- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Press Releases
Nov
Oct
Sep
- Dr. Reddy's Annual Report on Form 20-F for year ended March 31, 2007 available on the company's website
- Dr. Reddy's commences operations in Philippines. Expands presence in the ASEAN region
- Dr. Reddy's receives USFDA approval for Ranitidine (Zantac™) Tablets, 150mg (OTC)
- Dr. Reddy's enters the Dermatology topical anti-fungal market with the launch of 'EbernetTM' - (Eberconazole)
Jul
Jun
May
Apr
- Dr. Reddy’s announces new R&D Chief
- Dr. Reddy's launches Reditux™ - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma
- Dr. Reddy's announces the launch of Zolpidem Tartrate tablets
- Dr. Reddy's employees awarded PG certificates from BITS Pilani
- Dr. Reddy's is the First Participant in United States Pharmacopoeia's New Pharmaceutical Ingredient Verification Programme
